Author(s)
Fatima Amanat
Published 24 Projects
Infectious Diseases Epidemiology Allergy And Immunology Immunology Covid19
Juan Manuel Carreno
Published 3 Projects
Microbiology Infectious Diseases Key Words Influenza A Virus Next
Shirin Strohmeier
Published 9 Projects
Immunology Microbiology Infectious Diseases Allergy And Immunology Influenza
Hala Alshammary
Published 4 Projects
Infectious Diseases Key Words Influenza A Virus Next Nosocomial Outbreak
Ana S. Gonzalez-Reiche
Published 5 Projects
Infectious Diseases Gastroenterology Key Words Influenza A Virus Next
Emilia M Sordillo
Published 5 Projects
Epidemiology Infectious Diseases Key Words Influenza A Virus Next
Harm van Bakel
Published 7 Projects
Microbiology Epidemiology Infectious Diseases Gastroenterology Key Words
Content
Video Abstract (AI generated) (01:18) Paper PreprintIn this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from subjects who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, that the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity. We also found a co-dominance of mAbs targeting the NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like backboost to seasonal human coronaviruses OC43 and HKU1 spike proteins. Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical viral isolate carrying E484K as well as extensive changes in the NTD was abolished, suggesting that a proportion of vaccine induced RBD binding antibodies may provide substantial protection against viral variants carrying E484K.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 3 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 3 years ago
Jignesh H. Parmar
0 views • 2 years ago
Winston A. Haynes
0 views • 2 years ago
Noam Mazor
0 views • 2 years ago
Global Immunotalks
182 views • 3 years ago
Cem Yuksel
345 views • 3 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Florian Krammer. (2021, Oct 30).The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD[Video]. Scitok. https://scitok.com/project/p/b5523fa0
Amanat Fatima. "The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD" Scitok, uploaded by Krammer Florian, 30 Oct, 2021, https://scitok.com/project/pb5523fa0
Florian Krammer. "The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD" Scitok. (Oct 30, 2021). https://scitok.com/project/p/b5523fa0
Florian Krammer (Oct 30, 2021). The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD Scitok. https://scitok.com/project/p/b5523fa0
Florian Krammer. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD[video]. 2021 Oct 30. https://scitok.com/project/p/b5523fa0
@online{al2006link, title={ The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD }, author={ Krammer, Florian }, organization={Scitok}, month={ Oct }, day={ 30 }, year={ 2021 }, url = {https://scitok.com/project/p/b5523fa0}, }